Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET..

Ann Oncol. 2015 Oct;26(10):2007-9. doi: 10.1093/annonc/mdv334. Epub 2015 Aug 11.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Drug Therapy, Combination
  • Erlotinib Hydrochloride / therapeutic use*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Prognosis
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors*
  • Pyrrolidinones / therapeutic use*
  • Quinolines / therapeutic use*

Substances

  • ARQ 197
  • Antineoplastic Agents
  • Pyrrolidinones
  • Quinolines
  • Erlotinib Hydrochloride
  • MET protein, human
  • Proto-Oncogene Proteins c-met